Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 55

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 55
---
,
financial condition and results of operations.

<div align='center'>31</div>

If NewGenIvf’s new solutions and services are not adopted by its clients, or if it fails to innovate and develop new offerings that are adopted by its clients, its revenue and results of operations may be adversely affected.

To date, NewGenIvf has derived
a substantial majority of its revenue from sales of its fertility services. As NewGenIvf operates in an evolving industry, its long-term
results of operations and continued growth will depend on its ability to successfully develop and market new successful solutions and
services to its clients. If its existing clients do not value and/or are not willing to make additional payments for such new solutions
or services, it could adversely affect its business, financial condition and results of operations. If NewGenIvf is unable to predict
clients’ preferences, if the markets in which NewGenIvf participates change, including in response to government regulation, or
if NewGenIvf is unable to modify its solutions and services on a timely basis, NewGenIvf may lose clients. Its results of operations would
also suffer if its innovations were not responsive to the needs of the clients, appropriately timed with market opportunity or effectively
brought to market.

If NewGenIvf fails to adapt and respond effectively to the changing medical landscape, changing regulations, changing client needs, requirements or preferences, its offerings may become less competitive.

The market in which NewGenIvf
competes is subject to a changing medical landscape and changing regulations, as well as changing client needs, requirements and preferences.
The success of its business will depend, in part, on its ability to adapt and respond effectively to these changes on a timely basis.
NewGenIvf’s business strategy may not effectively respond to these changes, and NewGenIvf may fail to recognize and position itself
to capitalize upon market opportunities. NewGenIvf may not have sufficient advance notice and resources to develop and effectively implement
an alternative strategy. There may be scientific or clinical changes that require it to change its solutions or that make its solutions
less competitive in the marketplace. If there are sensitivities to its model or its existing competitors and new entrants create new disruptive
business models and/or develop new solutions that clients prefer to its solutions, NewGenIvf may lose clients, and its results of operations,
cash flows and/or prospects may be adversely affected. The future performance of NewGenIvf’s business will depend in large part
on its